Federal recipient
Anacor Pharmaceuticals, Inc.
-$178,062 committed in FY2018–FY2020
- Parent company
- Pfizer Inc.
- District
- NY-12
- Location
- 235 E 42ND ST, New York, NY, 10017
- UEI
- HGNKDH1DLM86
- DUNS
- 128824484
- Also known as
- Anacor Pharmaceuticals Inc
How the money flows
Committed dollars by how federal money reaches Anacor Pharmaceuticals, Inc..
Top agencies
The agencies that pay Anacor Pharmaceuticals, Inc., by dollars committed.
Top programs
The assistance programs behind Anacor Pharmaceuticals, Inc.'s money, by dollars committed.
What they sell
Top products and services Anacor Pharmaceuticals, Inc. sells the government under contract, by dollars committed.
R&D- Medical: Other (Applied Research/Exploratory Development)
$7.8M
Awards
The largest individual awards to Anacor Pharmaceuticals, Inc..
Competition
How many of Anacor Pharmaceuticals, Inc.'s priced contract actions drew exactly one offer — a competition on paper with a single bidder. A high share doesn't prove anything improper; it's a flag worth a second look.
Multiple offers
2
100%
Committed by fiscal year
Dollars committed to Anacor Pharmaceuticals, Inc., per fiscal year (FY2018–FY2020).
How to read these numbers
- Committed to this recipient
The dollars agencies committed to them — signed contracts and awarded grants — counted in the year each action happened.
- Lifetime vs. a single year
The profile sections cover the recipient's full history on record; the headline total and the flow bar reflect the fiscal year picked at the top.
- “Active in FY X”
A fiscal-year award list shows every award with at least one action that year, at its full lifetime value — a different lens from the by-year chart, which splits each award across the years it was committed.
- Names come raw
Recipient names appear exactly as filed, and the government doesn't standardize them, so one organization can show up under a few spelling variants — worth checking near-duplicates before sizing one up.
- The colored bars
Every bar on this page splits by how the money moves:
Direct payments
